Neurotech International Ltd. (AU:NTI)
ASX:NTI
NTI Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.04
Previous CloseN/A
Volume11.09K
Average Volume (3M)768.84K
Market Cap
AU$16.85M
Enterprise ValueAU$6.81M
Total Cash (Recent Filing)AU$6.34M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding1,296,313,100
10 Day Avg. Volume770,041
30 Day Avg. Volume768,844
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.26
Price to Sales (P/S)6.36
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Debt / Low LeverageZero reported debt materially lowers solvency and interest-service risk, giving management flexibility to prioritize R&D and clinical programs. For a cash-burning biotech, a debt-free structure reduces near-term liquidity stress and preserves optionality to raise equity or non-debt financing more conservatively.
FY2025 Revenue ReboundA sharp revenue recovery indicates early commercial traction or milestone-related receipts, suggesting product or program validation. If sustained, this revenue base can scale with continued clinical progress and commercialization activities, reducing binary clinical risk over the medium term.
High Reported Gross MarginA reported 100% gross margin implies very favorable unit economics or low direct cost recognition, which can translate to strong operating leverage as sales scale. Sustained high gross margins enhance the path to profitability provided SG&A and R&D growth are controlled during commercialization.
Bears Say
Consistent Negative Operating And Free Cash FlowPersistent and worsening negative free cash flow indicates the business is not self-funding; accelerating cash burn as activity ramps raises near-term financing needs. This structural cash deficit increases dilution and funding risk and constrains long-term program execution if external capital is limited.
Deep Operating Losses And Negative MarginsOperating losses many times revenue show the current cost base far exceeds sales, meaning scale is required to reach break-even. Structural unprofitability increases reliance on external funding and raises execution risk that revenue growth may not outpace ongoing R&D and SG&A spend.
Eroding Equity And Volatile Capital BaseMaterial decline in shareholders' equity reflects accumulated losses or dilution, weakening the capital cushion. A smaller equity base limits financial flexibility, increases the likelihood of future dilutive raises, and can undermine investor confidence in funding prolonged clinical and commercialization timelines.
Neurotech International News
NTI FAQ
What was Neurotech International Ltd.’s price range in the past 12 months?
Neurotech International Ltd. lowest share price was AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is Neurotech International Ltd.’s market cap?
Neurotech International Ltd.’s market cap is AU$16.85M.
When is Neurotech International Ltd.’s upcoming earnings report date?
Neurotech International Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 155 days.
How were Neurotech International Ltd.’s earnings last quarter?
Neurotech International Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.
Is Neurotech International Ltd. overvalued?
According to Wall Street analysts Neurotech International Ltd.’s price is currently Overvalued.
Does Neurotech International Ltd. pay dividends?
Neurotech International Ltd. does not currently pay dividends.
What is Neurotech International Ltd.’s EPS estimate?
Neurotech International Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neurotech International Ltd. have?
Neurotech International Ltd. has 1,296,313,100 shares outstanding.
What happened to Neurotech International Ltd.’s price movement after its last earnings report?
Neurotech International Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.692%.
Which hedge fund is a major shareholder of Neurotech International Ltd.?
Currently, no hedge funds are holding shares in AU:NTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurotech International Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.91%
12-Months-Change
Fundamentals
Return on Equity
-87.19%
Trailing 12-Months
Asset Growth
5.87%
Trailing 12-Months
Company Description
Neurotech International Ltd.
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.
Technical Analysis
Atomo Diagnostics Ltd.
―
Adherium Ltd.
―
―
Control Bionics Ltd.
―
OncoSil Medical Ltd
―